Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.

Details

Serval ID
serval:BIB_BD3BE28C9923
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Journal
Gynecologic oncology
Author(s)
Giannone G., Scotto G., Katsaros D., De Giorgi U., Farolfi A., Borella F., Cosma S., Ferrero A., Mangiacotti S., Villa M., Tuninetti V., Ghisoni E., Turinetto M., Mittica G., Gemmiti S., Zavallone L., Aglietta M., Pasini B., Di Maio M., Valabrega G.
ISSN
1095-6859 (Electronic)
ISSN-L
0090-8258
Publication state
Published
Issued date
07/2021
Peer-reviewed
Oui
Volume
162
Number
1
Pages
80-87
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Hypersensitivity reactions (HSRs) to platinum are an important issue in the treatment of patients (pts) with ovarian cancer (OC). Germline BRCA mutations have been proposed as a risk factor. We aimed at evaluating the incidence and severity of HSRs to platinum in OC pts. with known BRCA status.
We retrospectively analyzed 432 pts. from 5 Italian Centers. In addition, we performed a systematic review and meta-analysis of published series.
Four hundred nine pts. received at least one prior platinum-based treatment line: 314 were BRCA wild type (77%) and 95 were BRCA mutated (23%). There was no statistical difference in exposure to platinum. Incidence of any grade HSRs was higher among BRCA mutated pts. [9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts. more than in BRCA wild type. A multivariable analysis showed that harboring a germline BRCA mutation was related to a higher incidence of HSRs (HR: 1.84, 95% CI 1.00-3.99, p = 0.05) while having received pegylated liposomal doxorubicin (PLD) was related to a lower incidence of HSRs (HR: 0.03 95% CI 0.004-0.22, p = 0.001). The systematic review confirmed the higher incidence of HSRs in BRCA mutated pts., though heterogeneity among series was significant.
In OC pts. with BRCA mutations, there is a significantly higher incidence of HSRs to carboplatin, not justified by longer drug exposure. On the other hand, PLD exerted a protective role in our series.
Keywords
BRCA, Hypersensitivity reactions, Ovarian cancer, Platinum salts
Pubmed
Web of science
Create date
11/05/2021 8:46
Last modification date
13/10/2021 5:42
Usage data